Derivation Web

source_b1264a6c2c7f4156

by researka:v2 · 2026-06-26 03:16:35.243958+04:00

# Hypothesis-Generating Brief: ABT-263 — full paper

## Abstract

Evidence-honesty note: 25/33 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. 32/33 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on ABT-263 across 33 accepted source papers and 1290 high-confidence extracted claims.

The evidence profile contains 1 direct clinical source, 26 adjacent clinical sources, and 6 mechanistic or model-system sources, with 46 cross-study disagreements across the evidence base.

Positive study-level signals are summarized in the immune and inflammation, longevity, contextual adjacent evidence outcome classes, null signals in the contextual adjacent evidence, mechanism, immune and inflammation outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that ABT-263 remains a bounded geroscience case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

## Methods

### Review type and protocol
This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-senolytics-v06-DAILY-2026-06-24T23-58-07Z-R2`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-24.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `senolytic AND aging AND human`
- `(dasatinib AND quercetin) AND aging`
- `fisetin AND senescence AND aging`
- `navitoclax AND senescent AND clinical`
- `senolytic AND clinical trial AND randomized`
- `(senolytic OR senescence) AND (longevity OR healthspan)`
- `(p16 OR SASP OR senescent cell) AND human AND clinical`
- `senotherapeutic AND older adults AND trial`
- `(senescent cell OR SASP) AND frailty AND human`
- `(dasatinib OR quercetin OR fisetin) AND safety AND tolerability`
- (... 5 additional queries; see `methods_pack.json` for the full list)

### Eligibility criteria
- Sources whose primary content addresses senolytics.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 646 records in the receipt-candidate union, 614 were classified as source candidates and 33 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| Receipt candidate union | 646 |
| Classified source candidates | 614 |
| No extractable claims | 26 |
| None-only claim binding | 1 |
| Mixed partial-or-none claim-binding candidates | 25 |
| Partial-only claim-binding candidates | 9 |
| Strict high-confidence sources | 4 |
| Admitted final sources | 33 |

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, immune and inflammation, longevity, mechanism, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Results
| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Contextual Adjacent Evidence | n=14; claims=822 | no extracted directional signal in 11/14 sources | 10 indirect; 1 protocol; 3 review | limited corpus depth in this outcome class |
| Immune and Inflammation | n=7; claims=138 | no extracted directional signal in 4/7 sources | 1 indirect; 2 mechanistic; 1 protocol; 3 review | limited corpus depth in this outcome class |
| Mechanism | n=4; claims=47 | no extracted directional signal in 4/4 sources | 4 mechanistic | limited corpus depth in this outcome class |
| Cardiometabolic | n=3; claims=112 | no extracted directional signal in 3/3 sources | 3 indirect | limited corpus depth in this outcome class |
| Skeletal, Fracture, and Bone | n=3; claims=118 | no extracted directional signal in 2/3 sources | 1 direct; 2 indirect | limited corpus depth in this outcome class |
| Deficiency Prevalence | n=1; claims=39 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |
| Longevity | n=1; claims=14 | positive signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |

















**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.




This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

### Contextual Adjacent Evidence Outcomes



14 included sources were assigned to this outcome class. Directional coding: null=11, positive=1, unclear=2. Directness coding: indirect=10, protocol=1, review=3.

### Immune Inflammation Outcomes





2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: review=2.

Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.

### Mechanism Outcomes



4 included sources were assigned to this outcome class. Directional coding: null=4. Directness coding: mechanistic=4.

### Cardiometabolic Outcomes



3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=3.

### Skeletal Fracture Bone Outcomes



3 included sources were assigned to this outcome class. Directional coding: mixed=1, null=2. Directness coding: direct=1, indirect=2.

### Deficiency Prevalence Outcomes



1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

### Longevity Outcomes



1 included source were assigned to this outcome class. Directional coding: positive=1. Directness coding: indirect=1.

## Limitations

Single-source outcome classes (Deficiency Prevalence, Longevity) are treated as hypothesis-generating and receive proportional narrative depth rather than standalone evidentiary weight.

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus does not contain a long-term, adequately powered randomized controlled trial in non-diabetic, community-dwelling older adults that uses a hard clinical endpoint (all-cause mortality, incident disability, or incident fracture) as the primary outcome. The single direct-A1 human RCT in the corpus, Farr 2024, is a phase 2 bone-metabolism study in postmenopausal women with mixed-direction biomarker results across endpoints. The two IPF pilot trials, Justice 2019 (n = 14, intermittent D+Q over three weeks) and Nambiar 2023 (n = 12, randomized 1:1), are feasibility/tolerability studies rather than efficacy studies. No mortality, cardiovascular-event, or fracture-incidence RCT is represented, which is a binding constraint on any causal claim.

In animal/preclinical evidence, several outcome classes in this synthesis are supported by only one source each, which means any direction signal cannot be replicated within the corpus. Translational relevance to humans remains uncertain. The cardiometabolic class is thinly populated outside of Wakita 2026 and Kawamoto 2026, and skeletal fracture bone is anchored almost entirely by Farr 2024 against two indirect sources (Lim 2026, Fan 2026). With single-source direction signals, the directional coding cannot be distinguished from study-specific idiosyncrasies, and these claims must be treated strictly as hypothesis-generating rather than as reproducible evidence.

Population specificity sharply bounds external validity. The two human senolytic RCTs with reported results enrolled narrow groups: Farr 2024 in postmenopausal women, and Justice 2019 plus Nambiar 2023 in IPF patients aged >50 years. Shimizu 2025 enrolled middle-aged humans, Gonzales 2022/2023 enrolled early or mild Alzheimer's disease patients, and the Schweiger 2025 and Silva 2024 protocols target elderly psychiatric and septic patients respectively. Men, younger adults, non-white racial and ethnic groups, and patients with multimorbidity are under-represented or absent. Preclinical generalization is also narrow: most mechanistic studies use aged C57BL/6 mice (e. For example, Mahoney 2026 in young 6-month versus old 27-month aortas; Novais 2026 in SM/J mice; Fang 2023 in female APP NL-F/NL-F mice), with some work in male Wistar rats (Falahatgaroshibi 2026), rabbits (Sengun 2026), and Drosophila (Miller 2023). Cross-species extrapolation to human aging therefore carries substantial uncertainty.

The endpoint scope is narrow and weighted toward biomarkers rather than function. Farr 2024 measures bone-turnover markers (P = 0.020, P = 0.024, P = 0.149, P = 0.035, P = 0.049, P = 0.004), Justice 2019 measures physical function and pulmonary function rather than senescence burden, and Gonzales 2023 measures cerebrospinal fluid IL-6 (P = 0.008) and GFAP (P = 0.028) rather than cognition as a primary outcome. The methodological caveat of Ioannidis 2005, that surrogate associations do not guarantee hard-outcome validity, applies in full to any inferential leap from senolytic-induced biomarker shifts to clinical anti-aging benefit.

Several clinically-relevant claims in this domain rest on mechanistic or preclinical evidence only. Senolytic-resistant senescent-cell biology (Tripathi 2025) and the paraptosis route (Furuuchi 2026) are characterized in vitro or in rodents, and the strongest pro-longevity result (Ichim 2026, P < 0.05) is in a doxorubicin-induced accelerated-aging mouse model rather than in normal aging. Where mechanism-to-clinic translation is implied but not demonstrated in the corpus, the claim cannot be supported by the available sources.

## Conclusion

For ABT-263, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

## What This Synthesis Adds

This synthesis maps 33 included sources on Senolytics across 8 outcome classes and 46 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 33 curated reference papers, the evidence base for senolytics shows a context-dependent profile. Positive signals appear in: immune inflammation, longevity. Null findings dominate: contextual other, mechanism. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The senolytics anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

Additional corpus sources included animal/preclinical evidence; the strongest unresolved contrast is the null vs positive between Mahoney 2025 and Schweiger 2025 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 1 | positive | direct interventional hard-endpoint gap |
| cardiometabolic | 0 | 3 | null | direct interventional hard-endpoint gap |
| immune and inflammation | 0 | 5 | null, positive, unclear | conflict-resolution gap |
| mechanism | 0 | 4 | null | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 0 | 14 | null, positive, unclear | conflict-resolution gap |
| skeletal, fracture, and bone | 1 | 2 | mixed, null | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: positive |
| P2 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null |
| P3 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 5 indirect sources; direction profile: null, positive, unclear |
| P4 | mechanism: direct interventional hard-endpoint gap | 0 direct and 4 indirect sources; direction profile: null |
| P5 | contextual adjacent evidence: conflict-resolution gap | 0 direct and 14 indirect sources; direction profile: null, positive, unclear |

### Next-Study Design Recommendation

The next high-yield study for Senolytics should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Tensions and Gaps

Additional corpus sources included animal/preclinical evidence; evidence-gap priority: The tension analysis separates claim-level disagreement counts from substantive cross-context evidence gaps. Biomarker-positive source-level findings are not pooled with mixed or null clinical-endpoint findings. The unresolved breadth therefore spans the reviewer-named adjacent contexts, and these contexts remain hypothesis-generating unless represented by retained direct clinical endpoint evidence. The manuscript reports 46 claim-level cross-study disagreements from the manifest; that number is a claim-level count, not an independently pooled source-pair count. Actually surfaced tensions include:
- Fan 2026 vs Farr 2024: surfaced tension/disagreement in Skeletal, Fracture, and Bone because directions are null versus mixed.
- Falahatgaroshibi 2026 vs Furuuchi 2026: surfaced tension/disagreement in Contextual Adjacent Evidence because directions are unclear versus null.
- Islam 2023 vs Jean 2024: surfaced tension/disagreement in Immune and Inflammation because directions are positive versus null.
## Evidence Snapshot

In animal/preclinical evidence, topic-fit rationale: Sources are retained only when they operationalize senolytics directly or provide adjacent/contextual boundary evidence for the same construct. 1/33 retained sources are classified as direct; adjacent, contextual, review-level, or mechanistic sources are reclassified as boundary evidence rather than used for broad efficacy claims. Representative source-fit checks: Nambiar 2023 (indirect; Contextual Adjacent Evidence), Falahatgaroshibi 2026 (indirect; Contextual Adjacent Evidence), Sengun 2026 (indirect; Contextual Adjacent Evidence), Justice 2019 (indirect; Contextual Adjacent Evidence), Mahoney 2026 (indirect; Contextual Adjacent Evidence).

Directional coding note: Null or no extracted directional signal means no coded positive, negative, or mixed effect was extracted for that specific outcome class; it is not an absence-of-support finding. Positive, negative, mixed, unclear, and null are outcome-specific codes, so a bounded rationale can be supported by adjacent or different outcome evidence while another outcome remains null or unclear. Contextual claims contain bibliographic background, mechanism, methods, exposure definitions, or population context rather than effect-direction evidence. When an outcome-class summary uses no extracted directional signal, it should state the source proportion, such as X/Y sources, to avoid ambiguity.

Evidence type metadata note: evidence-type labels are resolved against source excerpts; review, RCT/trial, and excerpt evidence are reclassified under the source classification map before claims are interpreted.

Source directness breakdown: 1/33 retained sources directly address the stated topic and aging-relevant hard endpoints; 32/33 are adjacent, contextual, review-level, or mechanistic and are used only to bound interpretation. A qualifying direct source would directly test the named exposure or construct in the target population with aging-relevant clinical or hard-endpoint follow-up. Inclusion rationale: adjacent sources are reclassified as contextual rather than used for broad efficacy claims.

### Source Outcome-Class Map

Tension-accounting note: disagreement counts are claim-level. Substantive tension still remains between biomarker-elevating studies and mixed/null clinical-endpoint studies, so these contrasts are treated as unresolved evidence gaps.

- Nambiar 2023: Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- In animal/preclinical evidence, Falahatgaroshibi 2026: The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.

- In animal/preclinical evidence, Sengun 2026: Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.

- Justice 2019: Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- In animal/preclinical evidence, Mahoney 2026: Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- Islam 2023: Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age: outcome=Immune and Inflammation; direction=positive; directness=indirect; tier=B2.

- Zhang 2025: Senolytic-loaded asymmetric wound dressing for targeted senescent cell clearance in diabetic wound healing: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- In animal/preclinical evidence, Wakita 2026: Comparative analysis of senolytic drugs reveals mitochondrial determinants of efficacy and resistance: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2.

- Fan 2026: Supramolecular delivery of senolytics enables targeted anti-senescence therapy and accelerated fracture healing: outcome=Skeletal, Fracture, and Bone; direction=null; directness=indirect; tier=B2.

- In animal/preclinical evidence, Kawamoto 2026: Reevaluating the senolytic activity of a GLS1 inhibitor and an anti-PD-1 antibody: toward greater reproducibility and methodological rigor: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2.

- Chen 2020: Is exercise a senolytic medicine? A systematic review: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.

- In animal/preclinical evidence, Lim 2026: DEL‐1 is an Endogenous Senolytic Protein that Inhibits Senescence‐Associated Bone Loss: outcome=Skeletal, Fracture, and Bone; direction=null; directness=indirect; tier=B2.

- Novais 2026: Dasatinib and quercetin senolytic treatment delays early onset intervertebral disc degeneration in SM/J mice: outcome=Mechanism; direction=null; directness=mechanistic; tier=C1.

- Peng 2026: Synergistic targeting of senolytic and senomorphic action with dual-engineered biomimetic macrophage nanovesicles for mitigating osteoarthritis: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- In animal/preclinical evidence, Su 2026: Senolytics alleviate cyclophosphamide-induced premature ovarian insufficiency by eliminating senescent cells: outcome=Deficiency Prevalence; direction=null; directness=indirect; tier=B2.

- Tripathi 2025: Senolytic‐Resistant Senescent Cells Have a Distinct SASP Profile and Functional Impact: The Path to Developing Senosensitizers: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- Shimizu 2025: Preliminary Data on the Senolytic Effects of Agrimonia pilosa Ledeb. Extract Containing Agrimols for Immunosenescence in Middle-Aged Humans: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Comparison Study: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- Cadar 2025: Senolytic Treatment With Dasatinib and Quercetin Reshapes Influenza‐Specific CD8 T Cell Responses During Infection in Aged, Vaccinated Mice: outcome=Immune and Inflammation; direction=unclear; directness=mechanistic; tier=C1.

- Farr 2024: Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial.: outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=direct; tier=A1.

- Silva 2024: Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multicenter, randomized, adaptive allocation clinical trial: outcome=Immune and Inflammation; direction=null; directness=protocol; tier=D1.

- In animal/preclinical evidence, Ichim 2026: Synergistic senolytic–regenerative therapy significantly extends healthspan and lifespan: outcome=Longevity; direction=positive; directness=indirect; tier=B2.

- Furuuchi 2026: Natural senolytic activity of Rhodiola rosea extract alleviates age-associated phenotypes via paraptosis: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2.

- In animal/preclinical evidence, Gonzales 2022: Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (SToMP-AD): A Pilot Clinical Trial: outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2.

- Effect of Natural Senolytic 2024: Effect of Natural Senolytic Agents & NLRP3 Inhibitors on Osteoarthritis: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.

- Delval 2026: Senolytic Treatment Reduces Acute and Chronic Lung Inflammation in an Aged Mouse Model of Influenza: outcome=Immune and Inflammation; direction=positive; directness=mechanistic; tier=C1.

- Schweiger 2025: Protocol for a pilot clinical trial of the senolytic drug combination Dasatinib Plus Quercetin to mitigate age-related health and cognitive decline in mental disorders: outcome=Contextual Adjacent Evidence; direction=positive; directness=protocol; tier=D1.

- Jean 2024: Senolytic effects of exercise in human muscles require acute inflammation.: outcome=Immune and Inflammation; direction=null; directness=review; tier=B2.

- Fang 2023: Senolytic Intervention Improves Cognition, Metabolism, and Adiposity in Female APP NL-F/NL-F Mice: outcome=Mechanism; direction=null; directness=mechanistic; tier=C1.

- In animal/preclinical evidence, Mahoney 2025: Senolytic treatment with fisetin reverses age-related endothelial dysfunction partially mediated by SASP factor CXCL12: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.

- Gonzales 2023: Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.: outcome=Immune and Inflammation; direction=null; directness=review; tier=B2.

- Tripathi 2025b: Senolytic-Resistant Senescent Cells Have a Distinct SASP Profile and Functional Impact: The Path to Developing Senosensitizers: outcome=Immune and Inflammation; direction=null; directness=review; tier=B2.

- Avila 2024: Effect of senolytic drugs in young female mice chemically induced to estropause: outcome=Mechanism; direction=null; directness=mechanistic; tier=C1.

- In animal/preclinical evidence, Miller 2023: Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease: outcome=Mechanism; direction=null; directness=mechanistic; tier=C1.

### Load-Bearing Included Studies

- Additional corpus sources included animal/preclinical evidence; Farr 2024; tier=A1; directness=direct; endpoint=skeletal fracture bone; direction=mixed; representative statistic=P = 0.004.
- Nambiar 2023; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.
- Falahatgaroshibi 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.01.
- Sengun 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
- Justice 2019; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=p ≤ .05.
- Mahoney 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.465.
- Islam 2023; tier=B2; directness=indirect; endpoint=immune inflammation; direction=positive; representative statistic=p ≤ 0.0001.
- Zhang 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.
- Wakita 2026; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=null.
- Fan 2026; tier=B2; directness=indirect; endpoint=skeletal fracture bone; direction=null.

### Source Outcome-Class Map















- Chen 2020: Is exercise a senolytic medicine? A systematic review: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.



























### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Additional corpus sources included animal/preclinical evidence; severity 4 null vs positive: Mahoney 2025 vs Schweiger 2025; Schweiger 2025 (positive on contextual other) vs Mahoney 2025 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Effect of Natural Senolytic 2024 vs Schweiger 2025; Schweiger 2025 (positive on contextual other) vs Effect of Natural Senolytic 2024 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Nambiar 2023 vs Schweiger 2025; Schweiger 2025 (positive on contextual other) vs Nambiar 2023 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Silva 2024 vs Islam 2023; Islam 2023 (positive on immune inflammation) vs Silva 2024 (null on immune inflammation) — partial conflict
- Severity 4 null vs positive: Shimizu 2025 vs Schweiger 2025; Schweiger 2025 (positive on contextual other) vs Shimizu 2025 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Schweiger 2025 vs Tripathi 2025; Schweiger 2025 (positive on contextual other) vs Tripathi 2025 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Schweiger 2025 vs Zhang 2025; Schweiger 2025 (positive on contextual other) vs Zhang 2025 (null on contextual other) — partial conflict
- Severity 4 null vs positive: Schweiger 2025 vs Peng 2026; Schweiger 2025 (positive on contextual other) vs Peng 2026 (null on contextual other) — partial conflict

## References

- **Nambiar 2023.** _Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability._ eBioMedicine, 2023. DOI: 10.1016/j.ebiom.2023.104481. PMID: 36857968.
- **Falahatgaroshibi 2026.** _The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke._ Pharmaceuticals, 2026. DOI: 10.3390/ph19030431. PMID: 41901278.
- **Sengun 2026.** _Senolytic reduction of senescent cells mitigates atrial arrhythmia vulnerability in aging rabbits._ Heart rhythm, 2026. DOI: 10.1016/j.hrthm.2026.01.007. PMID: 41513056.
- **Justice 2019.** _Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study._ EBioMedicine, 2019. DOI: 10.1016/j.ebiom.2018.12.052. PMID: 30616998.
- **Mahoney 2026.** _Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12._ Aging Cell, 2026. DOI: 10.1111/acel.70500. PMID: 42021544.
- **Islam 2023.** _Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age._ Aging Cell, 2023. DOI: 10.1111/acel.13767. PMID: 36637079.
- **Zhang 2025.** _Senolytic-loaded asymmetric wound dressing for targeted senescent cell clearance in diabetic wound healing._ Materials Today Bio, 2025. DOI: 10.1016/j.mtbio.2025.102741. PMID: 41560809.
- **Wakita 2026.** _Comparative analysis of senolytic drugs reveals mitochondrial determinants of efficacy and resistance._ Nature Aging, 2026. DOI: 10.1038/s43587-025-01057-z. PMID: 41611832.
- **Fan 2026.** _Supramolecular delivery of senolytics enables targeted anti-senescence therapy and accelerated fracture healing._ Journal of Nanobiotechnology, 2026. DOI: 10.1186/s12951-026-04138-2. PMID: 41709294.
- **Kawamoto 2026.** _Reevaluating the senolytic activity of a GLS1 inhibitor and an anti-PD-1 antibody: toward greater reproducibility and methodological rigor._ EMBO Reports, 2026. DOI: 10.1038/s44319-026-00740-5. PMID: 41933117.
- **Chen 2020.** _Is exercise a senolytic medicine? A systematic review._ Aging Cell, 2020. DOI: 10.1111/acel.13294. PMID: 33378138.
- **Lim 2026.** _DEL‐1 is an Endogenous Senolytic Protein that Inhibits Senescence‐Associated Bone Loss._ Advanced Science, 2026. DOI: 10.1002/advs.202509263. PMID: 41556369.
- **Novais 2026.** _Dasatinib and quercetin senolytic treatment delays early onset intervertebral disc degeneration in SM/J mice._ Bone Research, 2026. DOI: 10.1038/s41413-026-00526-4. PMID: 41974671.
- **Peng 2026.** _Synergistic targeting of senolytic and senomorphic action with dual-engineered biomimetic macrophage nanovesicles for mitigating osteoarthritis._ Bioactive Materials, 2026. DOI: 10.1016/j.bioactmat.2025.11.047. PMID: 41625497.
- **Su 2026.** _Senolytics alleviate cyclophosphamide-induced premature ovarian insufficiency by eliminating senescent cells._ European Journal of Histochemistry : EJH, 2026. DOI: 10.4081/ejh.2026.4537. PMID: 42011821.
- **Tripathi 2025.** _Senolytic‐Resistant Senescent Cells Have a Distinct SASP Profile and Functional Impact: The Path to Developing Senosensitizers._ Aging Cell, 2025. DOI: 10.1111/acel.70358. PMID: 41462575.
- **Shimizu 2025.** _Preliminary Data on the Senolytic Effects of Agrimonia pilosa Ledeb. Extract Containing Agrimols for Immunosenescence in Middle-Aged Humans: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Comparison Study._ Nutrients, 2025. DOI: 10.3390/nu17040667. PMID: 40004995.
- **Cadar 2025.** _Senolytic Treatment With Dasatinib and Quercetin Reshapes Influenza‐Specific CD8 T Cell Responses During Infection in Aged, Vaccinated Mice._ Aging Cell, 2025. DOI: 10.1111/acel.70345. PMID: 41462563.
- **Farr 2024.** _Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial._ Nat Med, 2024. DOI: 10.1038/s41591-024-03096-2. PMID: 38956196.
- **Silva 2024.** _Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multicenter, randomized, adaptive allocation clinical trial._ Trials, 2024. DOI: 10.1186/s13063-024-08474-2. PMID: 39434114.
- **Ichim 2026.** _Synergistic senolytic–regenerative therapy significantly extends healthspan and lifespan._ Journal of Translational Medicine, 2026. DOI: 10.1186/s12967-026-08221-y. PMID: 42260530.
- **Furuuchi 2026.** _Natural senolytic activity of Rhodiola rosea extract alleviates age-associated phenotypes via paraptosis._ iScience, 2026. DOI: 10.1016/j.isci.2026.115607. PMID: 42028013.
- **Gonzales 2022.** _Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (SToMP-AD): A Pilot Clinical Trial._ The Journal of Prevention of Alzheimer's Disease, 2022. DOI: 10.14283/jpad.2021.62. PMID: 35098970.
- **Effect of Natural Senolytic 2024.** _Effect of Natural Senolytic Agents & NLRP3 Inhibitors on Osteoarthritis._ 2024. Identifier unavailable; no DOI or PMID in source metadata.
- **Delval 2026.** _Senolytic Treatment Reduces Acute and Chronic Lung Inflammation in an Aged Mouse Model of Influenza._ Aging Cell, 2026. DOI: 10.1111/acel.70480. PMID: 41952036.
- **Schweiger 2025.** _Protocol for a pilot clinical trial of the senolytic drug combination Dasatinib Plus Quercetin to mitigate age-related health and cognitive decline in mental disorders._ F1000Research, 2025. DOI: 10.12688/f1000research.151963.2. PMID: 40443429.
- **Jean 2024.** _Senolytic effects of exercise in human muscles require acute inflammation._ Aging (Albany NY), 2024. DOI: 10.18632/aging.205827. PMID: 38752873.
- **Fang 2023.** _Senolytic Intervention Improves Cognition, Metabolism, and Adiposity in Female APP NL-F/NL-F Mice._ bioRxiv preprint, 2023. DOI: 10.1101/2023.12.12.571277.
- **Mahoney 2025.** _Senolytic treatment with fisetin reverses age-related endothelial dysfunction partially mediated by SASP factor CXCL12._ bioRxiv preprint, 2025. DOI: 10.1101/2025.08.13.670216.
- **Gonzales 2023.** _Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial._ Nat Med, 2023. DOI: 10.1038/s41591-023-02543-w. PMID: 37679434.
- **Tripathi 2025b.** _Senolytic-Resistant Senescent Cells Have a Distinct SASP Profile and Functional Impact: The Path to Developing Senosensitizers._ bioRxiv preprint, 2025. DOI: 10.1101/2025.08.27.672709.
- **Avila 2024.** _Effect of senolytic drugs in young female mice chemically induced to estropause._ bioRxiv preprint, 2024. DOI: 10.1101/2024.05.22.595355.
- **Miller 2023.** _Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease._ Frontiers in Neurology, 2023. DOI: 10.3389/fneur.2023.1271941. PMID: 37840914.

### Background References

*Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*

- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.

{
  "article_type": "evidence_map",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "3726e8e5-b134-4576-990e-fdee76613fab",
  "title": "Hypothesis-Generating Brief: ABT-263 \u2014 full paper"
}